174 related articles for article (PubMed ID: 38418086)
1. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
Brinkhuis F; Goettsch WG; Mantel-Teeuwisse AK; Bloem LT
BMJ; 2024 Feb; 384():e077391. PubMed ID: 38418086
[TBL] [Abstract][Full Text] [Related]
2. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
3. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rosian K; Wild C; Simon J
Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
Vokinger KN; Kesselheim AS; Glaus CEG; Hwang TJ
JAMA Health Forum; 2022 Aug; 3(8):e222685. PubMed ID: 36200635
[TBL] [Abstract][Full Text] [Related]
5. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
6. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
[No Abstract] [Full Text] [Related]
7. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
8. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
9. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
10. Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?
Cramer A; Sørup FKH; Christensen HR; Petersen TS; Karstoft K
Lancet Oncol; 2023 Sep; 24(9):e385-e394. PubMed ID: 37657479
[TBL] [Abstract][Full Text] [Related]
11. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
Ruof J; Knoerzer D; Dünne AA; Dintsios CM; Staab T; Schwartz FW
Health Policy; 2014 Nov; 118(2):242-54. PubMed ID: 25194474
[TBL] [Abstract][Full Text] [Related]
12. Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union.
Manellari S; Musazzi UM; Rocco P; Minghetti P
Int J Pharm; 2023 Jul; 642():123193. PubMed ID: 37394157
[TBL] [Abstract][Full Text] [Related]
13. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic medicine regulatory approvals through the European Centralised Procedure, 1999-2017: Clinical efficacy considerations.
Morgan-Warren PJ
Eur J Ophthalmol; 2020 Mar; 30(2):321-349. PubMed ID: 30832499
[TBL] [Abstract][Full Text] [Related]
15. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
16. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
Erhel F; Scanff A; Naudet F
Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
[TBL] [Abstract][Full Text] [Related]
17. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis.
Ivama-Brummell AM; Marciniuk FL; Wagner AK; Osorio-de-Castro CGS; Vogler S; Mossialos E; Tavares-de-Andrade CL; Naci H
Lancet Reg Health Am; 2023 Jun; 22():100506. PubMed ID: 37235087
[TBL] [Abstract][Full Text] [Related]
18. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, clinical benefit and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020.
Martínez-Barros H; Pousada-Fonseca Á; Pedreira-Bouzas J; Clopés-Estela A
Farm Hosp; 2024 May; ():. PubMed ID: 38797624
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]